Effects of combination therapy with pirenzepine and famotidine on tetragastrin-stimulated gastric secretion in humans.
To determine the combined effects of the H2-receptor antagonist famotidine (FAM) and M1-receptor antagonist pirenzepine (PZ) on tetragastrin-stimulated acid production, 10 mg of FAM was intravenously injected into 6 healthy volunteers, alone and in combination with 20 mg of PZ. Physiologic saline was administered separately for control purposes. Compared with physiologic saline, both FAM and the FAM + PZ combination significantly reduced gastric secretion, acidity, acid output, and pepsin secretion. Concomitant use of PZ significantly enhanced FAM-induced reduction of overall gastric secretion, but did not enhance decreases in acid output, acidity, or pepsin secretion. These results indicate that combination therapy with intravenous FAM and PZ may be more useful than monotherapy with FAM in the treatment of gastroduodenal bleeding.
Misawa
T
T
Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka.
Chijiiwa
Y
Y
Fujishima
H
H
Harada
N
N
Nawata
H
H
D000328:Adult; D015738:Famotidine / Q000008:administration & dosage*; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010890:Pirenzepine / Q000008:administration & dosage*; D013268:Stimulation, Chemical; D013758:Tetragastrin / Q000494:pharmacology*
D013758:Tetragastrin; D010890:Pirenzepine; D015738:Famotidine